Tag Archives: healthcare reform

The 'S' Word in Healthcare Reform

by Tom Norton In little more than two years, the main elements of the HCR will take hold across the nation.  As implementation continues to ramp up, one of the more intriguing questions surrounding its activation is, is the “S” word being realized?…That is, “S” as in “savings.” Are the much publicized “savings” that were projected [...]
Posted in Guest Blog, Regulatory, Strategy, healthcare | Also tagged , , , , | 3 Comments

IPAB : An HCR Acronym You Need to Understand

Tom Norton throws some light on the much-vaunted Independent Payment Advisory Board. Working towards our top issue for the June edition of the HCR Monthly Review, I continue to be struck by the amount of macroeconomic data that will be driving the new HCR law. Indeed, most of the key performance measures in the 2010 statute [...]
Posted in Regulatory, healthcare | Also tagged , , , , , | Leave a comment

Should Doctors Shoulder Healthcare Costs?

As the debate over the rising costs of new drug R&D and brand name medications rages on, physicians are increasingly doing their part to minimize collateral damage inflicted upon the patient. A new report from Bain & Company — The new cost-conscious doctor: changing America’s healthcare landscape — reveals that, increasingly, physicians believe that part of [...]
Posted in healthcare | Also tagged , , , , | Leave a comment

How Will Accountable Care Organizations Hit Drug Sales?

It’s not yet clear whether physicians will rush to form accountable care organizations (ACOs) in light of newly proposed Centers for Medicare and Medicaid Services (CMS) guidelines, which are lengthy, but pharmaceutical companies hoping to do business with ACOs will have to show that expensive brand drugs can offer not just better health outcomes, but [...]
Posted in Legal, News, Regulatory, Sales, Strategy, healthcare | Also tagged , , , , | Leave a comment

US Mid-Term Elections: What It Means for Pharma

Daily News Nugget US Mid-Term Elections:  What it Means for Pharma Drink up, even if it’s  only old wine in new bottles… Yesterday’s mid-term congressional poll barely changes the stakes for pharma in its pursuit of its US legislative and regulatory agenda.    The key message coming out of the results is stalemate on the big issues like [...]
Posted in Op-Ed, Regulatory | Also tagged , , , , , , | 2 Comments